Adastra Holdings Ltd. Stock

Equities

XTRX

CA00654D1006

Pharmaceuticals

Market Closed - Canadian Securities Exchange 13:22:39 2024-04-26 EDT 5-day change 1st Jan Change
0.215 CAD +4.88% Intraday chart for Adastra Holdings Ltd. 0.00% -2.27%
Sales 2022 13.3 18.17 Sales 2023 22.22 30.38 Capitalization 12.31M 16.83M
Net income 2022 -4M -5.47M Net income 2023 -3M -4.1M EV / Sales 2022 1,272,975 x
Net Debt 2022 2.93M 4.01M Net Debt 2023 2.26M 3.1M EV / Sales 2023 655,990 x
P/E ratio 2022
-3.46 x
P/E ratio 2023
-3.14 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 97.72%
More Fundamentals * Assessed data
Dynamic Chart
Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adastra Holdings Ltd. Announces Appointment of Lachlan Mcleod as Interim Chief Executive Officer CI
Adastra Holdings Ltd. Announces Resignation of Smoke Wallin from Its Board of Directors CI
Adastra Holdings Announces Executive Changes CI
Adastra Holdings Ltd. Appoints Andrew Hale, MBA, BSAE, PMP to its Board of Directors CI
Adastra Holdings Ltd. Announces Record Total Purchase Orders Received in January and February CI
Adastra Holdings Ltd. Announces Resignation of Michael Forbes as Director and Corporate Secretary, Effective March 29, 2024 CI
Adastra Holdings Ltd. Announces Resignation of Michael Forbes as CEO, Effective March 29, 2024 CI
Adastra Holdings Ltd. Receives Purchase Order from the Alberta Gaming, Liquor & Cannabis CI
Adastra Holdings Brief: Announcing it has received a Purchase Order for C$1,047,439 from Alberta Gaming, Liquor & Cannabis MT
XORTX Therapeutics Brief: Says Submitted a New Patent for the Treatment of Chronic Kidney Disease MT
Adastra Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Adastra Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
XORTX Therapeutics Announces PKD Presentation MT
Adastra Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day+4.88%
Current month+2.38%
1 month+7.50%
3 months+7.50%
6 months-14.00%
Current year-2.27%
More quotes
1 week
0.20
Extreme 0.195
0.23
1 month
0.18
Extreme 0.18
0.26
Current year
0.17
Extreme 0.17
0.29
1 year
0.17
Extreme 0.17
0.54
3 years
0.11
Extreme 0.105
2.00
5 years
0.11
Extreme 0.105
2.97
10 years
0.11
Extreme 0.105
2.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 37 23-02-13
Members of the board TitleAgeSince
Director/Board Member - 21-07-13
More insiders
Date Price Change Volume
24-04-26 0.215 +4.88% 501
24-04-25 0.205 0.00% 5,610
24-04-23 0.205 +5.13% 3,400
24-04-22 0.195 -9.30% 2,466
24-04-19 0.215 -10.42% 19,046

Delayed Quote Canadian Securities Exchange, April 26, 2024 at 01:22 pm

More quotes
Adastra Holdings Ltd. is a Canada-based company, which is engaged in the supply and manufacturing of ethnobotanical and cannabis products. The Company serves medical markets and is engaged in therapeutic applications. The Company’s Phyto Extractions and Endgame Extracts brands distribute cannabis concentrate products through retailers at approximately 2,000 locations across Canada. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. It partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market. Its subsidiaries include Adastra Labs Holdings (2019) Ltd., Adastra Labs Inc., 1178562 B.C. Ltd., Adastra Brands Inc., Chemia Analytics Inc., 1225140 B.C. Ltd and 1204581 B.C. Ltd.
More about the company